Noveko International Inc. achieves key milestone toward FDA 510K accreditation of its antimicrobial face masks

    It has also filed its submission with Health Canada and initiated
    compliance requirements pursuant to European guidelines for CE Marking.

    (EKO-TSX Venture Exchange)

    MONTREAL, June 21 /CNW Telbec/ - NOVEKO INTERNATIONAL INC. ("Noveko" or
"the Company") is pleased to announce that its subsidiary Noveko Inc. has
accomplished the key milestone toward the FDA 510K accreditation of its two
antimicrobial face masks: the Noveko 3xEZ and the 5dEZR. At a formal meeting
with the FDA, Noveko Inc. received FDA approvals and high accolades for the
achieved advancements and the information provided on the supporting test
protocols. Consequently, Noveko Inc. was assigned a pre-IDE number
(investigational device exemption), which will enable it to complete its
submission with the requested support data in the coming weeks.
    "Due to the unique nature and application of the antimicrobial agents
required to design our face masks, we will conduct our final test protocols in
collaboration with Ciba Expert Services and FDA-accredited Nelson Laboratories
(Utah, U.S.). We expect to obtain 510K accreditation for our two types of
antimicrobial face masks by September 2007," indicated Dr. Konstantin Goranov,
Chief Technology Officer of Noveko Inc.

    An antimicrobial filtration and comfort performance that is superior to
    common face masks and unique worldwide

    The assignment of a pre-IDE number by the FDA follows the conclusive
results of a series of testing completed in late April 2007 on the two face
masks - Noveko 3xEZ (surgical mask) and 5dEZR (surgical respirator) - at
Nelson Laboratories in compliance with the standard ASTM 2100 (American
Society for Testing and Materials Standards) and NIOSH (National Institute for
Occupational Safety and Health) protocols. This series of testing proved that
these two types of face masks designed using Noveko's patented antimicrobial
technology - and targeted to specialized laboratory and health care
institution personnel as well as the general public - demonstrated an
antimicrobial filtration performance that is superior to and unmet by any
other face mask available on the world market today. The Noveko face masks
were tested at concentrations 50 times higher than the standards for common
surgical masks, proving that they represent a highly effective antimicrobial
protection barrier.
    Furthermore, the Noveko 3xEZ and 5dEZR face masks were submitted to
bio-compatibility tests performed pursuant to ISO 10993 requirements, as well
as to cellular cytotoxicity, irritation and dermal sensitization tests. Not
only did the tests show no reaction, they also highlighted the comfort
features of these face masks which allow easy, comfortable breathing.
    All the bio-efficacy and toxicology data were presented to the leadership
of the Control Devices Branch, Center for Devices and Radiological Health,
FDA, in May 2007.

    Health Canada and CE Marking

    Noveko Inc. recently filed its accreditation application with Health
Canada. It has also initiated compliance requirements pursuant to European
guidelines in order to apply to its face masks the CE Marking, which is
mandatory for European market clearance.


    Noveko International Inc. currently has three subsidiaries: S.A.S. ECM
(France), Noveko Inc. and Bolduc Leroux Inc. (BLI). ECM specializes in the
design and marketing of portable real-time ultrasound scanners for use in
veterinary and human medicine. Noveko Inc. develops the Company's biomedical
and environmental business, specifically its patented antimicrobial filtration
technology and derivative products (antimicrobial face masks and filters). For
its part, BLI specializes in the custom processing and distribution of steel
products based on client specifications and designs. It has also developed and
markets a line of downdraft particle extraction tables for various industrial,
commercial and pharmaceutical markets. Operating since September 2002, the
Company was listed on the TSX Venture Exchange on February 3, 2004.

    The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.

For further information:

For further information: André Leroux, Chairman of the Board and Chief
Executive Officer; Alain Bolduc, President and Chief Operating Officer, (514)

Organization Profile

Noveko International Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890